CA13 belongs to the carbonic anhydrase family, catalyzing the reversible hydration of CO₂:
This reaction is critical for physiological processes such as respiration, bone resorption, and renal acidification . Unlike other cytosolic isoforms, CA13 exhibits a unique tissue distribution, suggesting distinct roles in organs like the kidney, brain, and reproductive tissues .
Commercial CA13 antibodies are validated for specificity and performance across multiple platforms:
CA13 is differentially expressed across tissues and implicated in cancer biology:
Normal Tissues: High expression in colorectal mucosa, kidney tubules, and cerebral neurons .
Cancer: Overexpressed in colorectal tumors, with potential roles in modulating extracellular pH to support tumor growth .
Enzymatic Activity: CA13 has lower catalytic efficiency compared to CA II but shows unique sensitivity to inhibitors like acetazolamide .
Therapeutic Potential: Studies propose CA13 as a biomarker for hypoxia and a target for enzyme inhibitors in cancer therapy .
CA13 antibodies enable:
Diagnostic Assays: Quantifying CA13 levels in serum or tissue lysates via ELISA .
Pathological Studies: Immunohistochemical staining to map CA13 distribution in cancer vs. normal tissues .
Mechanistic Research: Investigating CA13's role in pH homeostasis using knockdown models .
Both antibodies undergo rigorous testing:
R&D Systems: Specificity confirmed via direct ELISA and Western blot under non-reducing conditions .
Sigma-Aldrich: Validated using protein microarrays and RNAseq to ensure minimal cross-reactivity .
Ongoing research aims to: